fda bpc 157 category 2 compounding 2023 BPC-157 Legal Status: Regulations and A step towards expanded patient

A step towards expanded patient access. This will allow patients to have conversations about these compounds in the clinical setting instead of resorting to a gray market without practitioner oversight or monitoring! I am getting so many messages there is a lot to review and a lot unfolding quickly! I want to take my time with the information and have been studying on rotations. Hopefully will get yall an only BREAKING: The FDA just reversed theIR 2023 peptide ban. 12 peptides were just pulled from the Category 2 restricted list: 1. BPC 157 2. Thymosin beta 4 fragment (TB 500) 3. Epitalon 4. GHK Cu (injectable) You may have heard buzz about 14 peptides potentially returning to legal compounding. Here's what we know: HHS Secretary RFK Jr. stated his intention to move these peptides from FDA Category 2 This just in: The FDA is proposing to move 14 commonly used peptides from Category 2 to Category 1 on the compounding review list If finalized, this shift could significantly change The FDA just put peptides like BPC 157, TB 500, and KPV on the clock. As a compounding pharmacist, this is literally my world and most people don't understand the regulatory nuance behind

SKU: 40054673545 · From southroadsurgery.com.au